Shares of Progenics Pharmaceuticals are up more than 20% in premarket trading after the company announced positive top-line results from its Phase III prostate cancer imaging tool PyL. The late-stage data sets up plans to seek regulatory approval in 2020.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,